IL1B and diabetes mellitus: Notably, among current diabetes treatment options used in our study; 10 mg/kg CurNPs and 50 mg/kg ZnONPs exhibited more anti-inflammatory power and showed significant suppression of expression levels of TNF-α, IL-1β as well as iNOS concentration in liver and pancreas.